June 14, 2017 07:00 PM EDT

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

John Carroll

Editor & Founder

The European venture group Medicxi is staking out some new terrain in biotech investing. And they’re bringing in two big players — Novartis and Google’s Verily …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

With No­var­tis and Google jump­ing in, Medicxi un­veils a $300M late-stage biotech fund with a transat­lantic scope

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role